Asset Details
Do you wish to reserve the book?
The emerging role of m6A methylation in prostate-related diseases: mechanisms and clinical implications
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The emerging role of m6A methylation in prostate-related diseases: mechanisms and clinical implications
Do you wish to request the book?
The emerging role of m6A methylation in prostate-related diseases: mechanisms and clinical implications
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The emerging role of m6A methylation in prostate-related diseases: mechanisms and clinical implications
2026
Overview
Prostate-related diseases, including prostatitis, benign prostatic hyperplasia (BPH), and prostate cancer (PCa), represent significant threats to the health of the aging male population worldwide. Despite their prevalence, the pathogenesis of prostate-related diseases has not been elucidated. Recent studies have shown that N 6 -methyladenosine (m 6 A) modification is widely involved in the progression of prostate-related diseases. In this review, we summarized recent advances in understanding the core m 6 A regulatory machinery comprising writers such as the methyltransferase-like 3 (METTL3)-METTL14 complex, erasers including fat mass and obesity-associated protein (FTO) and AlkB homolog 5 (ALKBH5), and readers, including the YTH domain-containing family proteins (YTHDFs), YTHDC proteins, insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs), and heterogeneous nuclear ribonucleoproteins (HNRNPs). Specifically, we elucidated how dysregulation of these components drives disease progression via alterations in cellular proliferation, differentiation, inflammatory responses, and stem cell dynamics. Notably, m 6 A modifications help shape the immunosuppressive landscape in PCa by modulating immune checkpoint expression, cytokine networks, and immune cell infiltration, thereby critically influencing therapeutic responses to immunotherapy. Furthermore, this review highlights the emerging diagnostic potential and therapeutic viability of m 6 A-targeted strategies, offering valuable insights for future clinical translation in prostate-related diseases.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
We currently cannot retrieve any items related to this title. Kindly check back at a later time.